NASDAQ · APRE
Healthcare · Biotechnology
$0.78
Up+$0.01 (+0.96%)
Updated Sep 15, 2026, 4:35 AM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
APRE does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning APRE.
APRE research
Company profile and research snapshot.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | Wedbush | Outperform | — |
| May 14, 2026 | Wedbush | Outperform | — |
| May 7, 2026 | Oppenheimer | Outperform | — |
| Mar 31, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 31, 2026 | Wedbush | Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 28, 2026
Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with
Benzinga · Aug 27, 2026
Gainers Celularity (NASDAQ:CELU) stock moved upwards by 134.0% to $2.06 during Thursday's regular session. The company's market cap stands at $25.0 million. Propanc Biopharma (NASDAQ:PPCB) stock increased by
Benzinga · Jul 30, 2026
Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity to demonstrate continued clinical progress with
Benzinga · Mar 3, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning APRE.
